STAAR Surgical Generates $464,000 in Cash from Operations During Thi...( STAAR Surgical Company Conde...),Health

Date:11/2/2009

======= ======= STAAR Surgical Company Condensed Consolidated Statements of Cash Flows (in 000's) Unaudited Nine Months Ended ----------------- October 2, September 26, 2009 2008 ---- ---- Cash flows from operating activities: Net loss $(4,717) $(13,735) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation of property and equipment 1,797 2,055 Amortization of intangibles 585 625 Amortization of discount 265 180 Fair value adjustment of warrant 74 60 Loss on disposal of property and equipment 96 89 Stock-based compensation expense 1,207 1,195 Loss on settlement of pre-existing distribution arrangement - 3,850 Change in pension liability 117 302 Other 51 (196) Changes in working capital, net of business acquisition: Accounts receivable (868) (2,482) Inventories 1,351 1,613 Prepaids, deposits and other current assets (28) 434 Accounts payable (225) (1,892) Other current liabilities 597 665
'/>"/>

SOURCE STAAR Surgical Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Related medicine technology :

1. STAAR Surgical to Present at the 20th Annual Oppenheimer Healthcare Conference in New York
2. STAAR Surgical Announces Third Quarter 2009 Earnings Release Date and Conference Call
3. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
5. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
6. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
7. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
10. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
11. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery